Factors influencing adherence to treatment with antihypertensive drugs in patients
DOI:
https://doi.org/10.35381/s.v.v8i2.4236Keywords:
Hypertension malignant, hypertension, hypertension portal, (Source: DeCS)Abstract
Objective: To analyze the factors that influence adherence to antihypertensive treatment in patients. Methods: Descriptive observational study, study population 58 hypertensive patients attending the Centro de Salud Tul Sur, Tulcán-Ecuador. Results and conclusion: Although adherence to antihypertensive treatment is high in some aspects, as shown by the fact that 69% of patients do not forget to take their medication, there are still challenges to be taken into account. Study population 58 hypertensive patients attending the Tul Sur Health Center, Tulcán-Ecuador.
Downloads
References
Tousoulis D. Arterial hypertension: New concepts in diagnosis and treatment?. Hellenic J Cardiol. 2020;61(3):145-147. http://dx.doi.org/10.1016/j.hjc.2020.08.003
Sheppard JP, Burt J, Lown M, et al. Optimizing Treatment for Mild Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomized controlled non-inferiority trial. BMJ Open. 2018;8(9):e022930. http://dx.doi.org/10.1136/bmjopen-2018-022930
Applegate WB, Williamson JD, Berlowitz D. Deprescribing Antihypertensive Medication in Elderly Adults. JAMA. 2020;324(16):1682. http://dx.doi.org/10.1001/jama.2020.16438
Peterson ED, Rich MW. Deprescribing Antihypertensive Medications for Patients Aged 80 Years or Older: Is Doing Less Doing No Harm?. JAMA. 2020;323(20):2024-2026. http://dx.doi.org/10.1001/jama.2020.4841
Sheppard JP, Burt J, Lown M, et al. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020;323(20):2039-2051. http://dx.doi.org/10.1001/jama.2020.4871
Eltayeb A, Khong TK. Treating hypertension with a pill containing very low doses of four antihypertensive agents compared with standard dose irbesartan. Drug Ther Bull. 2022;60(4):56-58. http://dx.doi.org/10.1136/dtb.2022.000014
Reeve E, Jordan V, Thompson W, et al. Withdrawal of antihypertensive drugs in older people. Cochrane Database Syst Rev. 2020;6(6):CD012572. http://dx.doi.org/10.1002/14651858.CD012572.pub2
Morselli F, Khong TK. Short-term effect of deprescribing antihypertensives in older people. Drug Ther Bull. 2022;60(8):118-119. http://dx.doi.org/10.1136/dtb.2022.000030
Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018;115(33-34):557-568. http://dx.doi.org/10.3238/arztebl.2018.0557
Ott C, Schmieder RE. Diagnosis and treatment of arterial hypertension 2021. Kidney Int. 2022;101(1):36-46. http://dx.doi.org/10.1016/j.kint.2021.09.026
Luna-López R, Ruiz Martín A, Escribano Subías P. Pulmonary arterial hypertension. Med Clin (Barc). 2022;158(12):622-629. http://dx.doi.org/10.1016/j.medcli.2022.01.003
Hengel FE, Sommer C, Wenzel U. Arterielle Hypertonie – Eine Übersicht für den ärztlichen Alltag [Arterial Hypertension]. Dtsch Med Wochenschr. 2022;147(7):414-428. http://dx.doi.org/10.1055/a-1577-8663
Tini G, Sarocchi M, Tocci G, et al. Arterial hypertension in cancer: The elephant in the room. Int J Cardiol. 2019;281:133-139. http://dx.doi.org/10.1016/j.ijcard.2019.01.082M
Dziedziak J, Zaleska-Żmijewska A, Szaflik JP, Cudnoch-Jędrzejewska A. Impact of Arterial Hypertension on the Eye: A Review of the Pathogenesis, Diagnostic Methods, and Treatment of Hypertensive Retinopathy. Med Sci Monit. 2022;28:e935135. http://dx.doi.org/10.12659/MSM.935135
Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res. 2018;128:322-326. http://dx.doi.org/10.1016/j.phrs.2017.10.007
Finocchi C, Sassos D. Headache and arterial hypertension. Neurol Sci. 2017;38(Suppl 1):67-72. http://dx.doi.org/10.1007/s10072-017-2893-x
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Dilan Steven Figueroa-Mejía, Ruth Alejandra Polanco-Muñoz, Brigitte Estefanía Pérez-Chamorro, Mónica Bustos-Villarreal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
